Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
Q3 Revenue of $9.1 million; an 11% increase year-over-year
- Q3 Revenue of $9.1 million; an 11% increase year-over-year
Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and collection initiatives
PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update. - Third quarter Net Revenue was $9.1 million, a $0.9 million increase over third quarter 2022.
- Loss from continuing operations in the third quarter of 2023 was $0.5 million, an improvement of $0.7 million from the prior-year quarter’s loss of $1.3 million.
- Q3 represented the 3rd consecutive quarter of double-digit volume and revenue growth in 2023 compared to 2022, according to Chris McCarthy, Chief Financial Officer.